COVID-19 can affect the heart
COVID-19 has a spectrum of potential heart manifestations with diverse mechanisms
The family of seven known human coronaviruses are known for their impact on the respiratory tract, not the heart. However, the most recent coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has marked tropism for the heart and can lead to myocarditis (inflammation of the heart), necrosis of its cells, mimicking of a heart attack, arrhythmias, and acute or protracted heart failure (muscle dysfunction). These complications, which at times are the only features of coronavirus disease 2019 (COVID-19) clinical presentation, have occurred even in cases with mild symptoms and in people who did not experience any symptoms. Recent findings of heart involvement in young athletes, including sudden death, have raised concerns about the current limits of our knowledge and potentially high risk and occult prevalence of COVID-19 heart manifestations.
The four “common cold” human coronaviruses—HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1—have not been associated with heart abnormalities. There were isolated reports of patients with Middle East respiratory syndrome (MERS; caused by MERS-CoV) with myocarditis and a limited number of case series of cardiac disease in patients with SARS (caused by SARS-CoV) (1). Therefore, a distinct feature of SARS-CoV-2 is its more extensive cardiac involvement, which may also be a consequence of the pandemic and the exposure of tens of millions of people to the virus.
What appears to structurally differentiate SARS-CoV-2 from SARS is a furin polybasic site that, when cleaved, broadens the types of cells (tropism) that the virus can infect (2). The virus targets the angiotensin-converting enzyme 2 (ACE2) receptor throughout the body, facilitating cell entry by way of its spike protein, along with the cooperation of the cellular serine protease transmembrane protease serine 2 (TMPRSS2), heparan sulfate, and other proteases (3). The heart is one of the many organs with high expression of ACE2. Moreover, the affinity of SARS-CoV-2 to ACE2 is significantly greater than that of SARS (4). The tropism to other organs beyond the lungs has been studied from autopsy specimens: SARS-CoV-2 genomic RNA was highest in the lungs, but the heart, kidney, and liver also showed substantial amounts, and copies of the virus were detected in the heart from 16 of 22 patients who died (5). In an autopsy series of 39 patients dying from COVID-19, the virus was not detectable in the myocardium in 38% of patients, whereas 31% had a high viral load above 1000 copies in the heart (6).
Accordingly, SARS-CoV-2 infection can damage the heart both directly and indirectly (see the figure). SARS-CoV-2 exhibited a striking ability to infect cardiomyocytes derived from induced pluripotent stem cells (iPSCs) in vitro, leading to a distinctive pattern of heart muscle cell fragmentation, with “complete dissolution of the contractile machinery” (7). Some of these findings were verified from patient autopsy specimens. In another iPSC study, SARS-CoV-2 infection led to apoptosis and cessation of beating within 72 hours of exposure (8). Besides directly infecting heart muscle cells, viral entry has been documented in the endothelial cells that line the blood vessels to the heart and multiple vascular beds. A secondary immune response to the infected heart and endothelial cells (endothelitis) is just one dimension of many potential indirect effects. These include dysregulation of the renin-angiotensin-aldosterone system that modulates blood pressure, and activation of a proinflammatory response involving platelets, neutrophils, macrophages, and lymphocytes, with release of cytokines and a prothrombotic state. A propensity for clotting, both in the microvasculature and large vessels, has been reported in multiple autopsy series and in young COVID-19 patients with strokes.
There is a diverse spectrum of cardiovascular manifestations, ranging from limited necrosis of heart cells (causing injury), to myocarditis, to cardiogenic shock (an often fatal inability to pump sufficient blood). Cardiac injury, as reflected by concentrations of troponin (a cardiac muscle–specific enzyme) in the blood, is common with COVID-19, occurring in at least one in five hospitalized patients and more than half of those with preexisting heart conditions. Such myocardial injury is a risk factor for in-hospital mortality, and troponin concentration correlates with risk of mortality. Furthermore, patients with higher troponin amounts have markers of increased inflammation [including C-reactive protein, interleukin-6 (IL-6), ferritin, lactate dehydrogenase (LDH), and high neutrophil count] and heart dysfunction (amino-terminal pro-B–type natriuretic peptide) (9).
More worrisome than the pattern of limited injury is myocarditis: diffuse inflammation of the heart, usually representing a variable admixture of injury and the inflammatory response to the injury that can extend throughout the three layers of the human heart to the pericardium (which surrounds the heart). Unlike SARS-associated myocarditis, which did not exhibit lymphocyte infiltration, this immune and inflammatory response is a typical finding at autopsy after SARS-CoV-2 infections. Involvement of myocytes, which orchestrate electrical conduction, can result in conduction block and malignant ventricular arrhythmias, both of which can lead to cardiac arrest.
Along with such in-hospital arrythmias, there have been reports of increased out-of-hospital cardiac arrest and sudden death in multiple geographic regions of high COVID-19 spread, such as the 77% increase in Lombardy, Italy, compared with the prior year (10). There have been many reports of myocarditis simulating a heart attack, owing to the cluster of chest pain symptoms, an abnormal electrocardiogram, and increased cardiac-specific enzymes in the blood, even in patients as young as a 16-year-old boy. When there is extensive and diffuse heart muscle damage, heart failure, acute cor pulmonale (right heart failure and possible pulmonary emboli), and cardiogenic shock can occur.
COVID-19–associated heart dysfunction can also be attributed to other pathways, including Takotsubo syndrome (also called stress cardiomyopathy), ischemia from endothelitis and related atherosclerotic plaque rupture with thrombosis, and the multisystem inflammatory syndrome of children (MIS-C). The underlying mechanism of stress cardiomyopathy is poorly understood but has markedly increased during the pandemic. MIS-C is thought to be immune-mediated and manifests with a spectrum of cardiovascular features, including vasculitis, coronary artery aneurysms, and cardiogenic shock. This syndrome is not exclusive to children because the same clinical features have been the subject of case reports in adults, such as in a 45-year-old man (11).
Recent series of COVID-19 patients undergoing magnetic resonance imaging (MRI) or echocardiography of the heart have provided some new insights about cardiac involvement (12–14). In a cohort of 100 patients recovered from COVID-19, 78 had cardiac abnormalities, including 12 of 18 patients without any symptoms, and 60 had ongoing myocardial inflammation, which is consistent with myocarditis (12). The majority of more than 1200 patients in a large prospective cohort with COVID-19 had echocardiographic abnormalities (13). This raises concerns about whether there is far more prevalent heart involvement than has been anticipated, especially because at least 30 to 40% of SARS-CoV-2 infections occur without symptoms. Such individuals may have underlying cardiac pathology.
Damaging the heart
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has the potential to directly and indirectly induce cardiac damage.
GRAPHIC: V. ALTOUNIAN/SCIENCE
To date, there have been four small series of asymptomatic individuals with bona fide infections who underwent chest computed tomography (CT) scans to determine whether there were lung abnormalities consistent with COVID-19. Indeed, half of the asymptomatic people showed lung CT features that were seen in patients with symptoms. But so far, there have been minimal cardiac imaging studies in people who test positive for SARS-CoV-2 or are seropositive but without symptoms. Furthermore, the time course of resolution or persistence of any organ abnormalities after SARS-CoV-2 infection has not yet been reported. With a high proportion of silent infections despite concurrent evidence of internal organ damage, there is a fundamental and large hole in our knowledge base.
In contrast to people without symptoms, there is a substantial proportion of people who suffer a long-standing, often debilitating illness, called long-COVID. Typical symptoms include fatigue, difficulty in breathing, chest pain, and abnormal heart rhythm. An immunologic basis is likely but has yet to be determined. Nor have such patients undergone systematic cardiovascular assessment for possible myocarditis or other heart abnormalities, such as fibrosis, which could account for some of the enduring symptoms. It would not be surprising in the future for patients to present with cardiomyopathy of unknown etiology and test positive for SARS-CoV-2 antibodies. However, attributing such cardiomyopathy to the virus may be difficult given the high prevalence of infections, and ultimately a biopsy might be necessary to identify virus particles to support causality.
Cardiac involvement in athletes has further elevated the concerns. A 27-year-old professional basketball player, recovered from COVID-19, experienced sudden death during training. Several college athletes have been found to have myocarditis (14), including 4 of 26 (15%) in a prospective study from Ohio State University (15), along with one of major league baseball's top pitchers. Collectively, these young, healthy individuals had mild COVID-19 but were subsequently found to have unsuspected cardiac pathology. This same demographic group—young and healthy—are the most common to lack symptoms after SARS-CoV-2 infections, which raises the question of how many athletes have occult cardiac disease? Systematic assessment of athletes who test positive for SARS-CoV-2, irrespective of symptoms, with suitable controls through some form of cardiac imaging and arrhythmia screening seems prudent until more is understood.
The most intriguing question that arises is why do certain individuals have a propensity for heart involvement after SARS-CoV-2 infection? Once recognized a few months into the pandemic, the expectation was that cardiac involvement would chiefly occur in patients with severe COVID-19. Clearly, it is more common than anticipated, but the true incidence is unknown. It is vital to determine what drives this pathogenesis. Whether it represents an individual's inflammatory response, an autoimmune phenomenon, or some other explanation needs to be clarified. Beyond preventing SARS-CoV-2 infections, the goal of averting cardiovascular involvement is paramount. The marked heterogeneity of COVID-19, ranging from lack of symptoms to fatality, is poorly understood. A newly emerged virus, widely circulating throughout the human population, with a panoply of disease manifestations, all too often occult, has made this especially daunting to unravel.
Acknowledgments
E.J.T. is supported by National Institutes of Health grant UL1 TR001114.
References and Notes
1
T. Y. Xiong, S. Redwood, B. Prendergast, M. Chen, Eur. Heart J. 41, 1798 (2020).
2
N. J. Matheson, P. J. Lehner, Science 369, 510 (2020).
3
F. Hikmet et al., Mol. Syst. Biol. 16, e9610 (2020).
4
A. Gupta et al., Nat. Med. 26, 1017 (2020).
5
V. G. Puelles et al., N. Engl. J. Med. 383, 590 (2020).
6
D. Lindner et al., JAMA Cardiol. 10.1001/jamacardio.2020.3551 (2020).
7
J. A. Perez-Bermejo et al., bioRxiv 265561, (2020).
8
A. Sharma et al., Cell Rep. Med. 10.1016/j.xcrm.2020.100052 (2020).
9
R. O. Bonow, G. C. Fonarow, P. T. O'Gara, C. W. Yancy, JAMA Cardiol. 5, 751 (2020).
10
E. Baldi et al., Lombardia CARe Researchers, N. Engl. J. Med. 383, 496 (2020).
11
S. Shaigany et al., Lancet 396, e8 (2020).
12
V. O. D. Puntmann et al., JAMA Cardiol. 10.1001/jamacardio.2020.3557 (2020).
13
M. R. Dweck et al., Eur. Heart J. 21, 949 10.1093/ehjci/jeaa178 (2020).
14
L. Huang et al., JACC Cardiovasc. Imaging S1936-878X(20)30403-4 (2020).
15
S. Rajpal et al., JAMA Cardiol. 10.1001/jamacardio.2020.4916 (2020).
(0)eLetters
eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter.
Log In to Submit a ResponseNo eLetters have been published for this article yet.
Information & Authors
Information
Published In
Science
Volume 370 | Issue 6515
23 October 2020
23 October 2020
Copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
This is an article distributed under the terms of the Science Journals Default License.
Article versions
You are viewing the most recent version of this article.
Submission history
Published in print: 23 October 2020
Acknowledgments
E.J.T. is supported by National Institutes of Health grant UL1 TR001114.
Authors
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Cite as
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Genetic screening for hypertension and COVID-19 reveals functional variation of SPEG potentially associated with severe COVID-19 in women, Frontiers in Genetics, 13, (2023).https://doi.org/10.3389/fgene.2022.1041470
- SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19, PLOS ONE, 18, 3, (e0282151), (2023).https://doi.org/10.1371/journal.pone.0282151
- High-depth sequencing characterization of viral dynamics across tissues in fatal COVID-19 reveals compartmentalized infection, Nature Communications, 14, 1, (2023).https://doi.org/10.1038/s41467-022-34256-y
- Acute mitral chodae rupture in the early postcovid in heavy physical active men. Case series, Sports medicine: research and practice, 12, 1, (77-85), (2022).https://doi.org/10.47529/2223-2524.2022.1.2
- E-Adoption of Emerging Technology in the Health Sector During COVID-19, International Journal of E-Adoption, 14, 3, (1-15), (2022).https://doi.org/10.4018/IJEA.309999
- TRPC3-Nox2 Protein Complex Formation Increases the Risk of SARS-CoV-2 Spike Protein-Induced Cardiomyocyte Dysfunction through ACE2 Upregulation, International Journal of Molecular Sciences, 24, 1, (102), (2022).https://doi.org/10.3390/ijms24010102
- Psychological and Mental Sequelae in Elite Athletes with Previous SARS-CoV-2 Infection: A Systematic Review, International Journal of Environmental Research and Public Health, 19, 24, (16377), (2022).https://doi.org/10.3390/ijerph192416377
- Mapping global trends in research of stem cell therapy for COVID-19: A bibliometric analysis, Frontiers in Public Health, 10, (2022).https://doi.org/10.3389/fpubh.2022.1016237
- A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients, Frontiers in Immunology, 13, (2022).https://doi.org/10.3389/fimmu.2022.930673
- Necroptosis and Viral Myocarditis: Tumor Necrosis Factor α as a Novel Biomarker for the Diagnosis of Viral Myocarditis, Frontiers in Cell and Developmental Biology, 10, (2022).https://doi.org/10.3389/fcell.2022.826904
- See more
Loading...
View Options
View options
PDF format
Download this article as a PDF file
Download PDFCheck Access
Log in to view the full text
AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your AAAS ID
- Purchase Access to Other Journals in the Science Family
- Account Help
Log in via OpenAthens.
Log in via Shibboleth.
More options
Purchase digital access to this article
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
RE: Direct and Indirect COVID-19 Effects on the Heart
The interesting, informative, and insightful perspective on how COVID-19 can affect the heart both directly and indirectly leads to questions as to whether similar effects occur for other primary internal and external organs other than the respiratory tract, such as the liver, kidney, brain, and ENT.
The SARS-CoV-2 virus has been identified as having "marked tropism for the heart and can lead to myocarditis (inflammation of the heart), necrosis of its cells, mimicking of a heart attack, arrhythmias, and acute or protracted heart failure (muscle dysfunction)", even for mild symptoms, or none at all.
It is crucial to determine how marked tropism, and other symptoms, for the heart might be affected by severe COVID-19, regardless of age, especially for patients with internal organ damage and other comorbidities.
As compared with SARS (or SARS-CoV) and MERS or (MERS-CoV), SARS-CoV-2 leads to more extensive cardiac involvement, and possibly also blood clots, which can lead to heart attacks and strokes, affect the lungs, heart, brain, and anywhere else the clot might travel through the blood.
COVID-19 would be expected to affect other internal and external organs, for which there are presently few observed clinical and non-clinical patient outcomes, besides the respiratory tract, and given the perspective, also the heart.
RE: Cardiomyocyte damage
Dexamethasone is recommended for COVID-19 patients receiving respiratory support. In the RECOVERY trial (https://www.nejm.org/doi/full/10.1056/NEJMoa2021436), 28-day overall mortality was 17% lower with dexamethosone than without. Mortality is a critical but rather crude endpoint and does not give detailed information about mechanisms. An open question is how much cardiomyocyte injury is a direct effect of the virus and how much may be ascribed to inflammatory processes. If inflammation plays a major role in cardiomyocyte damage, might dexamethasone earlier in the disease be beneficial in limiting long-term heart damage? A trial might use ECG and various cardiac imaging modalities to follow less severe/earlier cases of COVID-19 to assess cardiac function during the acute phase of the disease and long-term. Autopsy specimens would be another source of data. For patients not receiving respiratory support in the trial, there was no mortality difference, but would survivors who had not been on respiratory support but received dexamethasone have better cardiac outcomes? Of course, there is a risk of tamping down the immune response too much when trying to fight a viral disease.